Published in AIDS Weekly, August 18th, 1997
Based on safety data collected in this open label trial, as well as results of ongoing Phase II and III clinical studies, a larger international expanded access program for 1592 is expected to begin in 1998. 1592 is a nucleoside analogue reverse transcriptase inhibitor.
Investigators for the open label study are now actively enrolling patients through approximately 65 clinical trial sites located throughout the country. Entry into the study in...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.